Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus

Summary

This is a single-center, non-randomzied pilot study investigating a combination of targeted therapies as possible treatment for heart failure with preserved ejection fraction (HFpEF). The study interviention is a Low-Dose, Triple Polydiuretic Therapy (LDTPT, or polydiuretic) including loop diuretic (bumetanide), mineralocorticoid receptor antagonist (eplerenone), and Sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy (dapaglifozin).

Timeline

Start

2021-01-08

Primary completion

2022-01-01

Completion

2022-03-30

Drugs

Indications